S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in
NASDAQ:ONVO

Organovo Stock Forecast, Price & News

$12.78
-1.07 (-7.73 %)
(As of 02/25/2021 12:00 AM ET)
Add
Compare
Today's Range
$12.70
Now: $12.78
$15.50
50-Day Range
$11.30
MA: $14.68
$21.70
52-Week Range
$3.87
Now: $12.78
$23.92
Volume908,624 shs
Average Volume463,648 shs
Market Capitalization$90.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.85
Organovo Holdings, Inc., a biotechnology company, develops bioprinted human tissues based on its 3D human tissue platform technology that emulate human biology and diseases. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases; and NovoTissues liver product using cells from a liver donor and cells from an umbilical cord donor. The company was founded in 2007 and is headquartered in Solana Beach, California.
Organovo logo

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONVO
CUSIPN/A
Phone858-224-1000
Employees7
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.20 million
Book Value$4.08 per share

Profitability

Net Income$-18,710,000.00

Miscellaneous

Market Cap$90.96 million
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

0.67 out of 5 stars

Medical Sector

1251st out of 1,957 stocks

Biological Products, Except Diagnostic Industry

147th out of 177 stocks

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -
$12.78
-1.07 (-7.73 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ONVO News and Ratings via Email

Sign-up to receive the latest news and ratings for ONVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Organovo (NASDAQ:ONVO) Frequently Asked Questions

What stocks does MarketBeat like better than Organovo?

Wall Street analysts have given Organovo a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Organovo wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Organovo's next earnings date?

Organovo is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Organovo
.

How were Organovo's earnings last quarter?

Organovo Holdings, Inc. (NASDAQ:ONVO) issued its quarterly earnings data on Thursday, August, 8th. The medical research company reported ($1.00) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.00). The medical research company earned $0.67 million during the quarter, compared to analyst estimates of $0.77 million.
View Organovo's earnings history
.

How has Organovo's stock price been impacted by COVID-19?

Organovo's stock was trading at $5.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ONVO shares have increased by 145.8% and is now trading at $12.78.
View which stocks have been most impacted by COVID-19
.

When did Organovo's stock split? How did Organovo's stock split work?

Shares of Organovo reverse split on the morning of Wednesday, August 19th 2020. The 1-20 reverse split was announced on Monday, August 17th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 18th 2020. An investor that had 100 shares of Organovo stock prior to the reverse split would have 5 shares after the split.

Who are Organovo's key executives?

Organovo's management team includes the following people:
  • Mr. Keith E. Murphy, Exec. Chairman & Principal Exec. Officer (Age 49, Pay $1.39M)
  • Mr. Chris Heberlig CPA, M.B.A., Pres & CFO (Age 46)
  • Dr. Jeffrey N. Miner, Chief Scientific Officer
  • Mr. Steve E. Kunszabo, VP of Investor Relations & Corp. Communications
  • Mr. Thomas Einar Jurgensen, Gen. Counsel

What is Taylor Crouch's approval rating as Organovo's CEO?

3 employees have rated Organovo CEO Taylor Crouch on Glassdoor.com. Taylor Crouch has an approval rating of 38% among Organovo's employees. This puts Taylor Crouch in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Organovo's key competitors?

What other stocks do shareholders of Organovo own?

What is Organovo's stock symbol?

Organovo trades on the NASDAQ under the ticker symbol "ONVO."

Who are Organovo's major shareholders?

Organovo's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (5.36%), Jane Street Group LLC (0.23%) and Northern Trust Corp (0.22%).
View institutional ownership trends for Organovo
.

Which institutional investors are selling Organovo stock?

ONVO stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC.
View insider buying and selling activity for Organovo
or view top insider-selling stocks.

Which institutional investors are buying Organovo stock?

ONVO stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, and Northern Trust Corp.
View insider buying and selling activity for Organovo
or or view top insider-buying stocks.

How do I buy shares of Organovo?

Shares of ONVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Organovo's stock price today?

One share of ONVO stock can currently be purchased for approximately $12.78.

How much money does Organovo make?

Organovo has a market capitalization of $90.96 million and generates $2.20 million in revenue each year.

How many employees does Organovo have?

Organovo employs 7 workers across the globe.

What is Organovo's official website?

The official website for Organovo is www.organovo.com.

Where are Organovo's headquarters?

Organovo is headquartered at 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075.

How can I contact Organovo?

Organovo's mailing address is 440 STEVENS AVENUE SUITE 200, SOLANA BEACH CA, 92075. The medical research company can be reached via phone at 858-224-1000 or via email at [email protected]


This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.